Cerini （Ceritinib）

Cerini （Ceritinib） is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression or are intolerant to crizotinib therapy.